In the United States, penny stock market has always been very attractive for investors of all levels. More and more people are making fortunes with pink sheets, as their value is sky high now. There many examples of why a penny stock is worth hundreds of millions. Top penny stocks are usually the companies with quite good reputation, high gross profit margins and growth potential as per long-term outlook. Being a very cautious trader, I am aware of the risk in that kind of a market.

But, I also know how to handle it to make money on the side. Check it out too! I presume you came across this website to find more info on penny stock watch list 2018, correct, Below are the top 5 hot picks to watch and buy now (UPD: April 28th 2018). Hurry up traders! Today is an excellent time to invest! 1. General Cannabis Corp.

For those who have read my outlook at the end of 2017 are aware of my long positions and the entry price I bought the stock at (will give you an insight on this, too). CANN is a well-known company, which provide services of all levels in the cannabis industry. The range is quite imposing including cash and securities management, real estate, marketing and finance, consulting and advisory services.

143 million with shares outstanding over 35M. The one-year performance rate is incredible 101.5%. That is my fav stock and leader in swing trades. 7.9 in January 2018 (thanks to this alert) with very good profit in my pocket. Again, this a long-term investment. 4.03. CANN is growing and expending along with the cannabis market so I am confident in its upward trend going forward. A very interesting stock that deserves closer attention. To be honest it is a completely new joiner on my 2018 list but I am keeping my eye on it to catch its ascent.

Immunovaccine Inc. was founded in Canada and is a clinical-stage pharmaceutical company. The business covers development of products based on unique platform with embedded vaccine improvement, which focuses on T cells to activate therapies for cancer. The company has announced its DepoVax platform, which serves as a controller for antigens and adjuvant flowing into the immune system. 292 million with shares outstanding 137M. As regards financials, the company’s gross profit has increased whereas the net income has dropped.

2.13 and I am looking to buy long once my alert set-up confirmed. Stay tuned for more insights! Founded in 2009 the Company has yet made a revolution in treatments for diabetes symposium. In February 2017 at the Paris medical conference NEMAURA announced its very new sugarBEAT™ device that caused a mighty furore. SugarBEAT™ is a wireless and, what is important, non-invasive skin patch designed for those with Type I and Type II diabetes, which can be deployed for pre-diabetic purposes, too.

NEMAURA is a holding company that possesses specialty medical facilities to develop and test such kind of devices to help cure various forms of diabetes. 226 million of market cap. 466.366 to which slightly disappoints me, even though that happened due to one-time factors. I am keeping my eye on it to see if they can recover and get back to normal. Fortress Biotech Inc. is engaged in a biopharmaceutical business. The Company is currently working on the immunotherapy agent’s development to be used for the subsequent treatment of cancer.

A full-fledged project that will change the biopharmaceuticals industry forever. Their new product is called CNDO-109. This is a lysate which includes cell proteins and cell membrane fragments aimed at activating donor NK cells. In more simple words, the company is looking to unfold CNDO-109 to fight leukaemia diseases. 5.2. FBIO’s shares have not performed well enough over the last month but that stock is definitely on my next-to-buy radar.

The public float is over 51M with the average volume of 168K (still needs more liquidity). At this price, I don’t find it very attractive yet but still is a penny stock worth following. Our final top penny stock on the list - Cannabis Science Inc.. Industry - therapeutic drugs. The company engages in marijuana R&D.

All kinds of critical illnesses, which are being cured by phytocannabinoid-based products, is the primary goal of the company. Creation of cannabis-based pharmaceuticals, both psychoactive and non-psychoactive effects, to treat diseases and for general health, too. They are currently working on governmentally approved drugs, including CS-TATI1, CS-S/BCC-1 along with the development of neurological therapy.